LUCD logo

LUCD
Lucid Diagnostics Inc

1,782
Mkt Cap
$159.71M
Volume
387,224.00
52W High
$1.80
52W Low
$0.7501
PE Ratio
-1.29
LUCD Fundamentals
Price
$1.11
Prev Close
$1.16
Open
$1.17
50D MA
$1.13
Beta
0.64
Avg. Volume
666,952.84
EPS (Annual)
-$1.05
P/B
-5.34
Rev/Employee
$60,361.11
Loading...
Loading...
News
all
press releases
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) has been given an average rating of "Moderate Buy" by the five brokerages that are covering the company, MarketBeat reports. One equities...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Lucid Diagnostics Announces Positive Data from the Largest Reported...
PR Newswire·6d ago
News Placeholder
Wednesday Sector Laggards: Diagnostics, Medical Instruments & Supplies
In trading on Wednesday, diagnostics shares were relative laggards, down on the day by about 0.4%. Helping drag down the group were shares of Nutex Health, off about 5.7% and shares of Lucid...
Nasdaq News: Markets·19d ago
News Placeholder
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree PR Newswire NEW YORK, Nov. 20, 2025...
PR Newswire·25d ago
News Placeholder
Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Recommendation of "Moderate Buy" by Brokerages
Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the stock...
MarketBeat·27d ago
News Placeholder
Needham & Company LLC Reaffirms Buy Rating for Lucid Diagnostics (NASDAQ:LUCD)
Needham & Company LLC reissued a "buy" rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday...
MarketBeat·1mo ago
News Placeholder
Lucid Diagnostics (NASDAQ:LUCD) Announces Earnings Results
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) released its earnings results on Wednesday. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by...
MarketBeat·1mo ago
News Placeholder
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and...
PR Newswire·1mo ago
News Placeholder
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire NEW YORK, Nov. 13, 2025...
PR Newswire·1mo ago
News Placeholder
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -66.67% and -6.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest LUCD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.